New therapeutic options in congestive heart failure: Part II.
about
Heart failure with preserved ejection fraction.Cardiopulmonary exercise testing and its application.Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatmentNew developments in the pharmacological treatment of chronic heart failure.A review of levosimendan in the treatment of heart failure.Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs.Treatment of heart failure with decreased left ventricular ejection fraction.Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failureRodent models of heart failure: an updated review.Diastolic heart failure: the current understanding and approach for management with focus on intensive care unit patients.Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.Current treatment of heart failure with reduction of left ventricular ejection fraction.Emerging therapies for heart failure.Alterations in excitation-contraction coupling in chronically ischemic or hibernating myocardiumFeasibility of spinal cord stimulation in angina pectoris in patients with chronic pacemaker treatment for cardiac arrhythmias.Endoplasmic Reticulum Protein TXNDC5 Augments Myocardial Fibrosis by Facilitating Extracellular Matrix Protein Folding and Redox-Sensitive Cardiac Fibroblast Activation.Clinical implications of apoptosis in hypertensive heart disease
P2860
Q30420528-83EE610D-6F60-40FF-8905-F0D0C8DE2607Q34584702-21CC7E1A-0719-411F-A3DE-95540796E9C3Q34664894-24BFFCA4-CA44-4958-867A-BBD104CF3768Q35117060-2FA83E99-373B-4068-A297-E8672DDA0E82Q36013080-938FC6FA-D6A4-423E-8E17-77EED2278295Q36284079-843102D4-55F7-449F-B34F-D3C562109A94Q36953006-D43775E1-2CF8-4A65-BA08-C4BE0C62A760Q37264534-BA517394-5627-4486-9C5B-C101C4EFB6A0Q37996857-5026273D-F7F1-490D-80AD-015E4EA45126Q38025610-BBF1ABF6-1B92-4B7C-A224-CB65C69147CDQ38427211-31F07CC8-D143-477E-8885-BDF3D37C9B5FQ38965647-99027DB1-580B-44A8-A280-CB594321EFC9Q40409363-37FE84C7-A46A-425E-B3FD-61796F309D57Q42584078-96D3B5F7-AB3C-45A8-B66C-261F603B670FQ47380464-44499BED-C3F3-41D4-8D81-B5C805779A2FQ52657397-F0199F88-2ED5-4C84-AD9E-F59F747C40F9Q57395355-FF4DEA70-F9D5-4B3B-9B60-D2FFB7A46CCC
P2860
New therapeutic options in congestive heart failure: Part II.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
New therapeutic options in congestive heart failure: Part II.
@ast
New therapeutic options in congestive heart failure: Part II.
@en
New therapeutic options in congestive heart failure: Part II.
@nl
type
label
New therapeutic options in congestive heart failure: Part II.
@ast
New therapeutic options in congestive heart failure: Part II.
@en
New therapeutic options in congestive heart failure: Part II.
@nl
prefLabel
New therapeutic options in congestive heart failure: Part II.
@ast
New therapeutic options in congestive heart failure: Part II.
@en
New therapeutic options in congestive heart failure: Part II.
@nl
P1433
P1476
New therapeutic options in congestive heart failure: Part II.
@en
P2093
Marc A Pfeffer
P304
P356
10.1161/01.CIR.0000014771.38666.22
P407
P577
2002-05-01T00:00:00Z